Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Herman Chui

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
The Journal of Pathology. Clinical Research|February 9, 2018
Genomic profiling identifies <i>GPC5</i> amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomasM Herman Chui, Cherry Have, Lien N Hoang, et al.
The Journal of Pathology. Clinical Research|September 10, 2021
Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivationM Herman Chui, Ciyu Yang, Nikita Mehta, et al.
Oncotarget|December 17, 2019
<i>BRAF</i> -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinomaM Herman Chui, Susanne K Kjaer, Kirsten Frederiksen, et al.
Cancer Research|September 19, 2019
Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian CarcinomaM Herman Chui, Sasha A Doodnauth, Natalie Erdmann, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2014
Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinomaM Herman Chui, Yihong Wang, Ren-Chin Wu, et al.
Oncotarget|July 1, 2021
Correction: <i>BRAF</i> -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinomaM Herman Chui, Susanne K Kjaer, Kirsten Frederiksen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 22, 2022
Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumorsAmir Momeni Boroujeni, Elizabeth Kertowidjojo, Xinyu Wu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2024
Early Genetic Divergence of High-Grade Carcinomas Originating from Low-Grade Serous Ovarian NeoplasmsM Herman Chui, Qianqian Song, Jiarun Zhu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 27, 2025
Molecular subtypes and genomic landscape of undifferentiated and dedifferentiated endometrial cancerChristian Dagher, Pier Selenica, Amir Momeni-Boroujeni, et al.
Journal of Pathology Informatics|December 20, 2022
Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutationDavid Joon Ho, M Herman Chui, Chad M Vanderbilt, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
The Journal of Pathology. Clinical Research|February 9, 2018
Genomic profiling identifies <i>GPC5</i> amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomasM Herman Chui, Cherry Have, Lien N Hoang, et al.
The Journal of Pathology. Clinical Research|September 10, 2021
Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivationM Herman Chui, Ciyu Yang, Nikita Mehta, et al.
Oncotarget|December 17, 2019
<i>BRAF</i> -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinomaM Herman Chui, Susanne K Kjaer, Kirsten Frederiksen, et al.
Cancer Research|September 19, 2019
Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian CarcinomaM Herman Chui, Sasha A Doodnauth, Natalie Erdmann, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2014
Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinomaM Herman Chui, Yihong Wang, Ren-Chin Wu, et al.
Oncotarget|July 1, 2021
Correction: <i>BRAF</i> -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinomaM Herman Chui, Susanne K Kjaer, Kirsten Frederiksen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 22, 2022
Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumorsAmir Momeni Boroujeni, Elizabeth Kertowidjojo, Xinyu Wu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 10, 2024
Early Genetic Divergence of High-Grade Carcinomas Originating from Low-Grade Serous Ovarian NeoplasmsM Herman Chui, Qianqian Song, Jiarun Zhu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 27, 2025
Molecular subtypes and genomic landscape of undifferentiated and dedifferentiated endometrial cancerChristian Dagher, Pier Selenica, Amir Momeni-Boroujeni, et al.
Journal of Pathology Informatics|December 20, 2022
Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutationDavid Joon Ho, M Herman Chui, Chad M Vanderbilt, et al.
Pageof 5